NCT06678555

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

A Retrospective Study to Evaluate the Real-World Effectiveness of Lorlatinib Among ROS1-Positive NSCLC Patients

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 35 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. This study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called a ROS proto-oncogene 1. A gene is a part of your DNA that has instructions for making things your body needs to work. * have received at least 1 treatment before. All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take lorlatinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	Lorlatinib	Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.

Timeline

• Start date: 2025-07-04
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2024-11-07
• Last updated: 2026-02-05

Locations

1 site across 1 country: Taiwan